Emphysema
3 original drugsEmphysema has 3 FDA-approved novel treatments, led by Boehringer Ingelheim across 15 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Emphysema Market Leaders
Companies with the most FDA-approved novel Emphysema drugs.
Emphysema Clinical Pipeline by Phase
13 industry-sponsored trials across 8 sponsors
Novel Emphysema Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Emphysema.
Reformulations (4 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Emphysema Drug Targets
Molecular targets of approved and investigational Emphysema drugs — 15 targets tracked.
Generic Drugs (7 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs